The life science tools space is flourishing. Biomedical research output is at an all time high. Today’s guest says there are over 40,000 papers published each year on cancer biomarkers.
But very few of those become commercialized tests. Why?
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
www.mendelspod.com/subscribe
